The
monoclonal antibody therapy showed exceptional effectiveness in treating the patient's cancer.
这种单克隆抗体疗法在治疗患者的癌症方面表现出卓越的效果。
Monoclonal antibodies are used extensively in medical research for their specificity and ability to target particular diseases.
单克隆抗体因其特异性和针对特定疾病的靶向能力，在医学研究中被广泛应用。
A diagnostic test for COVID-19 was developed using
monoclonal antibodies, providing rapid and accurate results.
一种使用单克隆抗体开发的COVID-19诊断测试，提供了快速和精确的结果。
Monoclonal antibodies have revolutionized the treatment of autoimmune disorders, like rheumatoid arthritis.
单克隆抗体彻底改变了类风湿性关节炎等自身免疫疾病治疗领域。
Researchers are working on creating
monoclonal vaccines to combat emerging infectious diseases.
研究人员正在研发单克隆疫苗来对抗新兴传染病。
The production of
monoclonal antibodies is a complex process that requires specialized laboratory techniques.
单克隆抗体的生产是一个需要专门实验室技术的复杂过程。
Monoclonal antibodies can be engineered to recognize and neutralize a wide range of pathogens.
单克隆抗体可以被设计成识别并中和各种病原体。
In biotechnology,
monoclonal cells are selected and cloned to produce identical copies of a desired protein.
在生物技术中，选择并克隆单克隆细胞以产生所需蛋白质的相同副本。
Monoclonal antibodies are being investigated as potential treatments for various neurological disorders.
单克隆抗体正在被研究作为多种神经退行性疾病可能的治疗方法。
Monoclonal antibodies are gaining popularity in personalized medicine due to their tailored therapeutic potential.
单克隆抗体因其定制化的治疗潜力，在个性化医疗中越来越受欢迎。
Toripalimab is also the only anti-PD-1 monoclonal antibody included in the list for the treatment of melanoma.
托里帕利单抗也是唯一一种被列入黑色素瘤治疗名单的抗PD-1单克隆抗体。
Loqtorzi is the first US FDA-approved agent for NPC patients, and is a next-generation, programmed death receptor-1 monoclonal antibody, commonly known as PD-1 antibody.
Loqtorzi是美国食品药品监督管理局批准的第一种用于NPC患者的药物，是下一代程序性死亡受体-1单克隆抗体，通常被称为PD-1抗体。
This growth will be mainly fueled by the increasing demand for single-use products in advanced biopharmaceutical manufacturing such as monoclonal antibodies, vaccines and new therapies, he explained.
他解释说，这一增长将主要由先进生物制药制造中对单克隆抗体、疫苗和新疗法等一次性产品的需求增加推动。
We've already begun the process to align our global systems, processes, and capabilities to offer world-class solutions to customers working on all bioproduction platforms, including monoclonal antibodies, cell and gene therapies, and mRNA, and supports both therapy and vaccine manufacturing including COVID-19 in China," Wang added.
王补充道：“我们已经开始调整我们的全球系统、流程和能力，为在所有生物生产平台上工作的客户提供世界级的解决方案，包括单克隆抗体、细胞和基因疗法以及mRNA，并支持治疗和疫苗生产，包括中国的新冠肺炎。”。
GlaxoSmithKline is showcasing Mepolizumab, the world's first interleukin-5 monoclonal antibody, which has received approval in several countries, including the United States, for treatment on patients with inflammatory diseases caused by the presence of an abnormally increased number of eosinophils in the blood.
葛兰素史克公司正在展示世界上第一种白细胞介素-5单克隆抗体Mepolizumab，该抗体已在包括美国在内的几个国家获得批准，用于治疗因血液中嗜酸性粒细胞数量异常增加而引起的炎症性疾病患者。
At the beginning of last year, BeiGene worked with United Kingdom-based biopharmaceutical company EUSA Pharma to introduce a monoclonal antibody drug for neuroblastoma for Chinese patients.
去年年初， BeiGene与英国生物制药公司EUSA Pharma合作，为中国患者引进了一种针对神经母细胞瘤的单克隆抗体药物。
With the introduction of the monoclonal antibody drug, neuroblastoma patients are able to get medical treatment, bringing a chance of survival and cure for them.
随着单克隆抗体药物的引入，神经母细胞瘤患者现在能够接受医疗治疗，从而为他们带来了生存和治愈的希望。
In 2018, the NMPA included BeiGene's monoclonal antibody drug for neuroblastoma into the first batch of drugs on its badly as an imported drug for the clinical use catalog.
2018年，NMPA将 BeiGene 的一种针对神经母细胞瘤的单克隆抗体药物纳入首批临床急需境外新药名单，允许进口使用。
The fourth plant will mainly research, develop and produce anti-tumor monoclonal antibody and related cancer drugs independently, said Wang Xiaodong，founder of BeiGene and a foreign associate of Chinese Academy of Science, at the commencement ceremony.
“这座第四工厂将主要进行抗肿瘤单克隆抗体及相应抗癌药物的自主研发与生产，” BeiGene 创始人、中国科学院外籍院士王小东在奠基仪式上表示。
Lemzoparlimab, also known as TJC4, is an anti-CD47 monoclonal antibody discovered by the Shanghai-based company to treat multiple forms of cancer.
"Our mission is to develop monoclonal antibody-based research reagents, diagnostic reagents, and therapeutics for the global medical community," Zhang said.
The 2nd Merck Emerging Biotech China GrantThe grant recipients are:∙ Hangzhou ImmunoMAB Inc, for developing cell therapy, antibody-drug conjugates and bispecific monoclonal antibodies.
In May, Spevigo, a monoclonal antibody medication for treating rare skin diseases, filed for a new indication — the prevention of generalized pustular psoriasis.
At the exhibition hall, North China Pharmaceutical Group displayed Ormutivimab Injection, the first domestically produced rabies monoclonal antibody in China.
In March, Shanghai-based Junshi Biosciences granted commercialization rights of its monoclonal antibody in Southeast Asia to Excellmab, a joint venture of Rxilient Biotech.
China National Pharmaceutical Group Co Ltd, or Sinopharm, announced recently it had developed four Omicron-specific vaccine candidates, including inactivated, recombinant protein, and mRNA varieties, as well as an inhalable monoclonal antibody for COVID-19 prevention.
A bispecific antibody is a molecule designed to recognize two different antigens or two different epitopes on the same antigen to treat tumors and other diseases and therefore is widely believed to have superior clinical therapeutic effects compared with traditional monoclonal antibodies.
Some of them have been able to conduct world-class R&D of cutting-edge treatments, such as PD-1/PD-L1 inhibitors, anti-CD47 monoclonal antibodies, and other revolutionary cancer therapeutics.
他们中的一些已经能够进行世界级的前沿治疗的研发，比如PD-1/PD-L1抑制剂、抗CD47单克隆抗体，以及其他革命性的癌症治疗方法。
A recent case is I-Mab Biopharma's out-licensing deal with global drugmaker AbbVie Inc, for the rights of lemzoparlimab, an anti-CD47 monoclonal antibody developed by the Shanghai-based company to treat multiple forms of cancer.
最近的一个例子是，上海的I-Mab Biopharma公司将其开发的治疗多种癌症的抗CD47单克隆抗体lemzoparlimab的授权给了全球制药商艾伯维公司。
Previous clinical trials of agents developed to treat Ebola have shown monoclonal neutralizing antibodies can reduce viremia, attenuate virulence, substantially improve clinical symptoms and reduce the mortality of those infected.
The fully human monoclonal antibody was identified by screening blood samples of patients who recovered from COVID-19.
未经许可，严禁转发。QQ交流群：688169419